Find Clinical Trial

Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study.


← Back
Study Phase Phase 2
Therapeutic Area Rhumatology
Active Substance S201086
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS201086
Protocol CodeCL2-201086-002
EudraCT Code2017-004581-10


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.